leadforensics

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner

PHARMA REPORT

rss_Pharma.jpg...see all
Global Growth Hormone Drugs Market Forecast to 2027

Global Growth Hormone Drugs Market Forecast to 2027

Somatropin and Mecasermin Based Drugs, Innovator Generics and Biosimilars, Norditropin, Genotropin, Humatrope, Saizen, Nutropin, Omnitrope, Zomacton, R&D and Leading Companies

Product code: PHA0261

  • Publication date: 29/11/2017
  • Number of Pages: 184
  1. Report Details
  2. Table of Contents
  3. Companies Listed

Report Details

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 184-page report you will receive 78 tables and 106 figures– all unavailable elsewhere.

The 184-page report provides clear detailed insight into the Growth Hormone Drugs Market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

The Global Growth Hormone Drugs market was estimated at $3.8 billion in 2016 and is expected to grow at a CAGR of 3.6% during 2017-2027. Somatropin based drugs led the market with 98.9% of the market share.

Read on to discover how this definitive report can transform your own research and save you time.

The new market assessment benefits research, analysis and planning in seven main ways:
• World growth hormone drugs market revenue to 2027 – discover that industry’s overall sales potential
• Two product classes' revenues to 2027 – investigate categories at world level, finding the most lucrative and promising therapy classes
• Seven leading drugs’ revenues to 2027 – find sales predictions for top and emerging products, seeing how agents compete and succeed
• 7 national markets in the Americas, Europe and Asia covered, with forecasts to 2027 – discover the best countries for trade expansion
• Activities of established, rising and emerging companies – hear about firms’ products, capabilities, advances, collaborations and outlooks
• R&D for growth hormone medicines – investigate progress in that industry, exploring technological, clinical and commercial opportunities
• Analysis of what stimulates and restrains that industry and market – assess challenges, strengths, competition and opportunities, helping you succeed.

There you explore business intelligence with research, opinions and predictions found only in that work.

Trying our investigation now lets you discover trends, opportunities and prospects
For growth hormone drugs, our report shows you data, trends, opportunities and multilevel sales forecasts. So, avoid missing out. Instead please get that new analysis here now.

Report highlights

• 184-pages, 78 tables and 106 figures

• Growth Hormone Drugs Market Forecast from 2017 to 2027

• This report also breaks down the revenue forecast for the main submarkets:
• Innovator Generics
• Biosimilars
• Mecasermin based drugs
• Somatropin based drugs

Analysis of the Innovator Generics drugs market. Revenue forecasts to 2027 are provided for the following drugs:
• Norditropin
• Genotropin
• Humatrope
• Saizen
• Nutropin

Analysis of the Biosimilar drugs market. Revenue forecasts to 2027 are provided for the following drugs:
• Omnitrope
• Zomactan. Tev-tropin/ Growject

Analysis of key players in Growth Hormone Drugs
• Merck KGaA
• Roche
• Novartis
• Novo Nordisk
• Eli Lilly and Co.
• Pfizer Inc.

Regional Growth Hormone Drugs market forecasts from 2017-2027
• US forecast 2017-2027,
• Japan forecast 2017-2027
• Germany forecast 2017-2027
• UK forecast 2017-2027
• France forecast 2017-2027
• Italy forecast 2017-2027
• Spain forecast 2017-2027

Global Growth Hormone Drugs Market Forecast to 2027

Key questions answered
• How is the Growth Hormone Drugs market evolving?
• What is driving and restraining Growth Hormone Drugs market dynamics?
• How will each Growth Hormone Drugs submarket market grow over the forecast period and how much Sales will these submarkets account for in 2026?
• How will market shares of each Growth Hormone Drugs submarket develop from 2017-2027?
• Which individual technologies will prevail and how will these shifts be responded to?
• Which Growth Hormone Drugs submarket will be the main driver of the overall market from 2017-2027?
• How will political and regulatory factors influence regional Growth Hormone Drugs markets and submarkets?
• Will leading national Growth Hormone Drugs markets broadly follow macroeconomic dynamics, or will individual country sectors outperform the rest of the economy?
• How will market shares of the national markets change by 2026 and which nation will lead the market in 2026?
• Who are the leading players and what are their prospects over the forecast period?
• How will the sector evolve as alliances form during the period between 2017 and 2027?

• Target audience
• Leading Growth Hormone Drug Compaies
• Suppliers
• Contractors
• Technologists
• R&D staff
• Consultants
• Analysts
• CEO’s
• CIO’s
• COO’s
• Business development managers
• Investors
• Governments
• Agencies
• Industry organisations
• Banks

With our study you see how that market can develop and perform, benefiting your reputation for insight and authority.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Table of Contents

1. Report Overview
1.1 Global Growth Hormone Drugs Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report Include:
1.5 Who is This Report For?
1.6 Methodology
1.6.1 Primary Research
1.6.2 Secondary Research
1.6.3 Market Evaluation & Forecasting Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated visiongain Reports
1.9 About visiongain

2. Introduction to Growth Hormone Deficiency (GHD)
2.1 What is Growth Hormone?
2.2 What is GHD?
2.3 Diagnosis of GHD
2.4 Treatment of GHD

3. Epidemiology
3.1 US
3.2 EU
3.2.1 Denmark
3.2.2 UK
3.2.3 France
3.2.4 Belgium
3.2.5 Spain
3.3 Russia
3.4 Japan

4. Introduction to the Global Growth Hormone Drugs Market
4.1 Market Structure
4.2 Market Definition and Scope
4.3 Classification by Innovator Biologics or Biosimilars
4.3.1 Innovator Biologics
4.3.2 Biosimilars

5. Global Growth Hormone Drugs Market 2017-2027
5.1 Global Growth Hormone Drugs Market 2016
5.2 Global Growth Hormone Market Historical Revenue, 2011-2016
5.3 Global Growth Hormone Drugs Market Forecast 2017-2027
5.4 Market Segmentation by Innovator Biologics and Biosimilars
5.4.1 Global Growth Hormone: Innovator Biologics and Biosimilar Drugs Market Forecast 2017-2027
5.4.1.1 Innovator Drugs Market Forecast 2016-2027
5.4.1.2 Biosimilar Drugs Market Forecast 2016-2027
5.4.2 Innovator and Biosimilar Drugs Market Share Forecast 2017-2027
5.5 Market Segmentation by Molecule
5.5.1 Global Growth Hormone Drugs Historical Revenue 2011-2016
5.5.2 Global Growth Hormone Drugs Forecast 2017-2027
5.5.2.1 Somatropin Based Growth Hormone Drugs Market Forecast 2016-2027
5.5.2.2 Mecasermin Based Growth Hormone Drugs Market Forecast 2016-2027
5.5.3 Mecasermin and Somatropin Based Drugs Market Share Forecast 2017-2027
5.6 Global Growth Hormone Drugs Market Drivers, Restraints and Trends

6. Leading Growth Hormone Drugs
6.1 Snapshot of Growth Hormone Drugs’ 2016 Sales, Historical Sales, & Forecast 2017-2027
6.2 Innovator Drugs
6.2.1 Norditropin – Novo Nordisk
6.2.1.1 Drug Profile
6.2.1.2 Norditropin Historical Sales 2011-2016
6.2.1.3 Norditropin Revenue Forecast 2017-2027
6.2.1.4 Norditropin Sales by Geography, 2016
6.2.2 Genotropin – Pfizer
6.2.2.1 Drug Profile
6.2.2.2 Genotropin Historical Sales 2011-2016
6.2.2.3 Genotropin Revenue Forecast 2017-2027
6.2.2.4 Genotropin Sales by Geography, 2016
6.2.3 Humatrope – Eli Lilly
6.2.3.1 Drug Profile
6.2.3.2 Humatrope Historical Sales 2011-2016
6.2.3.3 Humatrope Revenue Forecast 2017-2027
6.2.3.4 Humatrope Sales by Geography, 2016
6.2.4 Saizen – Merck KGaA
6.2.4.1 Drug Profile
6.2.4.2 Saizen Historical Sales 2011-2016
6.2.4.3 Saizen Revenue Forecast 2017-2027
6.2.4.4 Saizen Sales by Geography, 2016
6.2.5 Nutropin, Nutropin AQ – Roche/Ipsen
6.2.5.1 Drug Profile
6.2.5.2 Nutropin, Nutropin AQ Historical Sales
6.2.5.3 Nutropin, Nutropin AQ Revenue Forecast 2017-2027
6.2.5.4 Nutropin, Nutropin AQ Sales by Geography, 2016
6.3 Biosimilars
6.3.1 Omnitrope – Novartis
6.3.1.1 Drug Profile
6.3.1.2 Omnitrope Historical Sales
6.3.1.3 Omnitrope Revenue Forecast 2017-2027
6.3.1.4 Omnitrope Sales by Geography, 2016
6.3.2 Zomactan / Tev-tropin / Growject - Ferring / JCR Pharmaceuticals
6.3.2.1 Drug Profile:

7. Leading National Markets Forecast 2017-2027
7.1 Geographical Breakdown of Global Growth Hormone Drugs Market, 2016
7.1.1 Region-wise Breakdown of Global Growth Hormone Drugs Market, 2016
7.1.2 Country-wise Breakdown of Global Growth Hormone Drugs Market, 2016
7.2 Region-wise Historical Sales of Global Growth Hormone Drugs Market, 2011-2016
7.3 Region-wise Forecast of Global Growth Hormone Drugs Market, 2017-2027
7.4 US Growth Hormone Drugs Market, 2016
7.4.1 US Growth Hormone Drugs Historical Sales, 2011-2016
7.4.2 US Growth Hormone Revenue Forecast, 2017-2027
7.5 EU5 Growth Hormone Drugs Market, 2016
7.5.1 EU5 Growth Hormone Historical Sales 2011-2016
7.5.2 EU5 Growth Hormone Revenue Forecast, 2017-2027
7.5.2.1 UK Growth Hormone Revenue Forecast, 2017-2027
7.5.2.2 Spain Growth Hormone Revenue Forecast, 2017-2027
7.5.2.3 Italy Growth Hormone Revenue Forecast 2017-2027
7.5.2.4 Germany Growth Hormone Revenue Forecast 2017-2027
7.5.2.5 France Growth Hormone Revenue Forecast, 2017-2027
7.6 Japan Growth Hormone Drugs Market, 2016
7.6.1 Japan Growth Hormone Drugs Historical sales, 2011-2016
7.6.2 Japan Growth Hormone Revenue Forecast, 2017-2027

8. Research and Development for Treating GHD
8.1 Active Pipeline Molecules
8.2 Novel Mechanism of Action of Pipeline Drugs
8.3 Clinical-stage Pipeline Molecules: Brief Overview
8.3.1 Pipeline Drugs in Registration
8.3.1.1 Macrilen (Macimorelin acetate, AEZS-130, EP 1572) – Aeterna Zentaris
8.3.2 Pipeline Drugs in Phase III
8.3.2.1 VRS-317 (Somavaratan) - Versartis
8.3.2.2 ACP-001 (TransCon Growth Hormone) – Ascendis Pharma
8.3.2.3 MOD-4023 (Somatrogon, Lagova, PF-06836922) – OPKO Health
8.3.2.4 NN-8640 (Somapacitan, NNC0195-0092) – Novo Nordisk
8.3.3 Pipeline Drugs in Phase II
8.3.3.1 GX-H9 (HL-2356, hGH-hyFc) – Genexine
8.3.3.2 HM10560A (Efpegsomatropin, LAPS-Hgh, LAPS-rhGH) – Hanmi Pharmaceutical
8.3.3.3 ALT-P1 (CJ-40002, hGH-NexP) – Alteogen
8.3.4 Pipeline Drugs in Phase I
8.3.4.1 CP-024 – Critical Pharmaceuticals
8.4 Discontinued Pipeline Molecules

9. Qualitative Analysis of the Global Growth Hormone Drugs Market
9.1 SWOT Analysis, 2016

10. Leading Companies in Global Growth Hormone Drugs Market, 2016
10.1 Growth Hormone Drugs Market Players Historical Sales
10.2 Key Players
10.2.1 Novo Nordisk
10.2.1.1 SWOT Analysis
10.2.2 Pfizer Inc.
10.2.2.1 SWOT Analysis
10.2.3 Eli Lily and Company
10.2.3.1 SWOT Analysis
10.2.4 Merck & Co., Inc
10.2.4.1 SWOT Analysis
10.2.5 Roche
10.2.5.1 SWOT Analysis
10.2.6 Novartis
10.2.6.1 SWOT Analysis

11. Executive Summary and Recommendations

12. Glossary
Associated visiongain Reports

Appendix A
About visiongain

Appendix B

Table of Tables
Table 1.1 Example of Growth Hormone Drugs Market by Regional Market Forecast 2017-2027 ($m, AGR %)
Table 3.1 Incidence Rate of GHD based on Age of Onset, Denmark
Table 3.2 Incidence & Prevalence of GHD Cases in Individuals Aged 0 to 20 years, by Diagnosis, in Cataluña, Spain
Table 3.3 Incidence & Prevalence of GHD Cases, Russia
Table 4.1 List of Innovator Biologics for the treatment of GHD
Table 5.1 Global Growth Hormone Drugs Market by Markets: Revenue ($m), and Market Share (%), 2016
Table 5.2 Global Growth Hormone Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 5.3 Comparative Overview of Key Growth Hormone Devices
Table 5.4 Global Growth Hormone Drugs Market Segmentation by Innovator Drugs and Biosimilars 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 5.5 Global Growth Hormone Drugs Market Segmentation by Innovator Drugs and Biosimilars 2016-2027: AGR (%)
Table 5.6 Global Growth Hormone Innovator Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 5.7 Global Growth Hormone Biosimilar Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 5.8 Global Growth Hormone Drugs Market Segmentation by Innovator Drugs and Biosimilars 2016-2027: Market Share (%)
Table 5.9 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Drugs 2016-2027: Historical Revenue ($m), AGR (%), CAGR (%)
Table 5.10 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Drugs 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 5.11 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Drugs 2016-2027: AGR (%)
Table 5.12 Global Somatropin Based Growth Hormone Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 5.13 Global Mecasermin Based Growth Hormone Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 5.14 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Drugs 2016-2027: Market Share (%)
Table 6.1 Leading Growth Hormone Drug Sales, Revenue($m), Market Share (%), 2016
Table 6.2 Norditropin: Drug Profile
Table 6.3 Norditropin Global Historical Sales: Revenue ($million), 2011-2016
Table 6.4 Norditropin Sales Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 6.5 Patent Expiry of Norditropin
Table 6.6 Genotropin: Drug Profile
Table 6.7 Genotropin Global Historical Sales: Revenue ($million), AGR (%), CAGR (%) 2011-2016
Table 6.8 Genotropin Sales Forecast 2016-2027: Revenue ($million), AGR (%), CAGR (%)
Table 6.9 Humatrope: Drug Profile
Table 6.10 Humatrope Global Historical Sales: Revenue ($m), AGR (%), CAGR (%) 2011-2016
Table 6.11 Humatrope Sales Forecast 2016-2027: Revenue ($million), AGR (%), CAGR (%)
Table 6.12 Saizen: Drug Profile
Table 6.13 Saizen Global Historical Sales: Revenue ($million), AGR (%), CAGR (%) 2011-2016
Table 6.14 Saizen Sales Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 6.15 Nutropin AQ: Drug Profile
Table 6.16 Nutropin and Nutropin AQ Combined Global Sales: Revenue ($million), 2011-2016
Table 6.17 Nutropin and Nutropin AQ Combined Sales Forecast 2016-2027: Revenue ($million), AGR (%), CAGR (%)
Table 6.18 Omnitrope: Drug Profile
Table 6.19 Omnitrope Global Sales: Revenue ($million), AGR (%), CAGR (%) 2011-2016
Table 6.20 Omnitrope Sales Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 6.21 Zomacton: Drug Profile
Table 7.1 Global Growth Hormone Drugs Market by Region: Revenue ($m), and Market Share (%), 2016
Table 7.2 Global Growth Hormone Drugs Market by Country: Revenue ($m), and Market Share (%), 2016
Table 7.3 Global Growth Hormone Drugs Market Historical Sales: Revenue ($m), AGR (%), CAGR (%), 2011-2016
Table 7.4 Global Growth Hormone Drugs Market by Region: AGR (%) 2012-2016
Table 7.5 Global Growth Hormone Drugs Market by Region: Historical Market Share 2011-2016 (%)
Table 7.6 Global Growth Hormone Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 7.7 Global Growth Hormone Drugs Market by Region: AGR (%) 2016-2027
Table 7.8 Global Growth Hormone Drugs Market by Region: Market Share Forecast 2017-2027 (%)
Table 7.9 List of Growth Hormone Drugs Approved in the US, 2017
Table 7.10 US Growth Hormone Drugs Market Historical Sales 2011-2016: Revenue ($m), AGR (%), CAGR (%)
Table 7.11 US Patent and Exclusivity Status of Growth Hormone Drugs Approved, 2017
Table 7.12 US Growth Hormone Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 7.13 EU5 Growth Hormone Drugs Market 2016: Global Market Share (%)
Table 7.14 EU5 Growth Hormone Drugs Market Historical Sales 2011-2016: Revenue ($m), AGR (%), CAGR (%)
Table 7.15 EU5 Growth Hormone Drugs Market by Region: Historical Market Share Forecast 2011-2016 (%)
Table 7.16 EU5 Growth Hormone Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 7.17 EU5 Growth Hormone Drugs Market By Region: Market Share Forecast 2017-2027 (%)
Table 7.18 EU5 Growth Hormone Drugs Market Forecast by Region: AGR 2016-2027 (%)
Table 7.19 Patent and Exclusivity Status of Growth Hormone Drugs Approved in the US, 2017
Table 7.20 UK Growth Hormone Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 7.21 List of Growth Hormone Drugs Approved in Spain, 2017
Table 7.22 Spain Growth Hormone Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 7.23 Italy Growth Hormone Drugs Market Forecast in Italy: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 7.24 Germany Growth Hormone Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 7.25 List of Growth Hormone Drugs Approved in France, 2017
Table 7.26 France Growth Hormone Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 7.27 Japan Growth Hormone Drugs Market Historical Sales 2011-2016: Revenue ($m), AGR (%), CAGR (%)
Table 7.28 Japan Growth Hormone Drugs Market Forecast Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 8.1: Active Pipeline Molecules under Development for Treating GHD
Table 8.2 Key Discontinued GHD Pipeline Candidates
Table 10.1 Key Drugs in the Global Growth Hormone Drugs Market
Table 10.2 Global Growth Hormone Drugs Market Players: Historical Revenue ($m), 2011-2016
Table 10.3 Novo Nordisk A/S: Overview
Table 10.4 Pfizer: Overview
Table 10.5 Eli Lilly and Company: Overview
Table 10.6 Merck: Overview 2016
Table 10.7 Roche: Overview
Table 10.8 Novartis: Overview

Table of Figures
Figure 1.1 Global Growth Hormone Drugs Market Segmentation Overview
Figure 1.2 Example of Growth Hormone Drugs Market by Regional Market Share Forecast 2017, 2022, 2027 (%)
Figure 2.1 Growth Hormone Signaling Pathway
Figure 4.1 Global Growth Hormone Drugs Market Segmentation Overview
Figure 5.1 Global Growth Hormone Drugs Market, Segmentation by Innovator Drugs and Biosimilars, Market Share 2016 (%)
Figure 5.2 Global Growth Hormone Drugs Market Segmentation by Molecule, Market Share 2016 (%)
Figure 5.3 Global Growth Hormone Drugs Market Historical Revenue 2011-2016: Revenue ($m), AGR (%)
Figure 5.4 Global Growth Hormone Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
Figure 5.5 Global Growth Hormone Drugs Market Segmentation by Innovator Drugs and Biosimilars, Revenue 2016 ($m)
Figure 5.6 Global Growth Hormone Drugs Market Segmentation by Innovator Drugs and Biosimilars, Market Share 2016 (%)
Figure 5.7 Global Growth Hormone Drugs Market Segmentation by Innovator Drugs and Biosimilars 2016-2027: Revenue ($m), Global AGR (%)
Figure 5.8 Global Growth Hormone Drugs Market Segmentation by Innovator Drugs and Biosimilars: Revenue 2016 and 2027 ($m), CAGR 2016-2027 (%)
Figure 5.9 Global Growth Hormone Drugs Market Segmentation by Innovator Drugs and Biosimilars 2016-2027: AGR (%)
Figure 5.10 Global Growth Hormone Innovator Drugs Market 2016-2027: Revenue ($m), AGR (%)
Figure 5.11 Global Biosimilar Drugs Market 2016-2027: Revenue ($m), Growth Hormone AGR (%)
Figure 5.12 Global Growth Hormone Drugs Market Segmentation by Innovator Drugs and Biosimilars 2016-2027: Market Share (%)
Figure 5.13 Global Growth Hormone Drugs Market Segmentation by Innovator Drugs and Biosimilars, Market Share Forecast 2017 (%)
Figure 5.14 Global Growth Hormone Drugs Market Segmentation by Innovator Drugs and Biosimilars: Market Share Forecast 2027 (%)
Figure 5.15 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Drugs, Revenue 2016 ($m)
Figure 5.16 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based, Market Share 2016 (%)
Figure 5.17 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Drugs 2011-2016: Revenue ($m), Global AGR (%)
Figure 5.18 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Drugs 2016-2027: Revenue ($m), Global AGR (%)
Figure 5.19 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Drugs: Revenue 2016 and 2027 ($m), CAGR 2016-2027 (%)
Figure 5.20 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Growth Hormone Drugs 2016-2027: AGR (%)
Figure 5.21 Global Somatropin Based Growth Hormone Drugs Market 2016-2027: Revenue ($m), AGR (%)
Figure 5.22 Global Mecasermin Based Growth Hormone Drugs Market 2016-2027 2016-2027: Revenue ($m), AGR (%)
Figure 5.23 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Drugs 2016-2027: Market Share (%)
Figure 5.24 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Drugs, Market Share Forecast 2017 (%)
Figure 5.25 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Drugs: Market Share Forecast 2027 (%)
Figure 5.26 Trends in Global Growth Hormone Drugs Market
Figure 5.27 Trends in Global Growth Hormone Drugs Market
Figure 6.1 Leading Growth Hormone Drug Sales, Revenue ($m), 2016
Figure 6.2 Leading Growth Hormone Drug Sales, Market Share (%), 2016
Figure 6.3 Growth Hormone Drugs Sales Forecast, Market Share (%), 2027
Figure 6.4 Leading Growth Hormone, Historical Sales, Revenue ($m), 2011-2016
Figure 6.5 Leading Growth Hormone Drugs, Historical Sales Trend, Revenue ($m), 2011-2016
Figure 6.6 Global Growth Hormone Innovator Drugs Market, Market Share by Individual Drug (%), 2016
Figure 6.7 Global Growth Hormone Innovator Drugs Market Forecast, Market Share by Individual Drug (%), 2027
Figure 6.8 Norditropin Global Sales: Revenue ($million), 2011-2016
Figure 6.9 Norditropin Sales Forecast 2016-2027: Revenue ($m), AGR (%)
Figure 6.10 Norditropin Sales by Geography: Market Share (%), 2016
Figure 6.11 Genotropin Global Sales: Revenue ($million), AGR (%), 2011-2016
Figure 6.12 Genotropin Sales Forecast 2016-2027: Revenue ($million), AGR (%)
Figure 6.13 Genotropin Sales by Geography: Market Share (%), 2016
Figure 6.14 Humatrope Global Sales: Revenue ($million), AGR (%), 2011-2016
Figure 6.15 Humatrope Sales Forecast 2016-2027: Revenue ($million), AGR (%)
Figure 6.16 Humatrope Sales by Geography: Market Share (%), 2016
Figure 6.17 Saizen Global Sales: Revenue ($million), AGR (%), 2011-2016
Figure 6.18 Saizen Sales Forecast 2016-2027: Revenue ($million), AGR (%)
Figure 6.19 Saizen Sales by Geography: Market Share (%), 2016
Figure 6.20 Nutropin and Nutropin AQ Combined Global Sales: Revenue ($million), 2011-2016
Figure 6.21 Nutropin and Nutropin AQ Combined Sales Forecast 2016-2027: Revenue ($million), AGR (%)
Figure 6.22 Nutropin and Nutropin AQ Combined Sales by Geography: Market Share (%), 2016
Figure 6.23 Global Growth Hormone Biosimilars Market Share by Individual Drug (%), 2016
Figure 6.24 Global Growth Hormone Biosimilars Market Share by Individual Drug (%), 2027
Figure 6.25 Omnitrope Global Sales: Revenue ($million), AGR (%), CAGR (%) 2011-2016
Figure 6.26 Omnitrope Sales Forecast 2016-2027: Revenue ($million), AGR (%)
Figure 6.27 Omnitrope Sales by Geography: Market Share (%), 2016
Figure 7.1 Global Growth Hormone Drugs Market Segmentation by Region/Country
Figure 7.2 Global Growth Hormone Drugs Market by Region: Revenue ($m)
Figure 7.3 Global Growth Hormone Drugs Market by Region: Market Share 2016 (%)
Figure 7.4 Global Growth Hormone Drugs Market by Country: Revenue ($m)
Figure 7.5 Global Growth Hormone Drugs Market by Country: Market Share (%)
Figure 7.6 Global Growth Hormone Drugs Market Historical Revenue by Region: Revenue ($m), Global AGR (%), 2011-2016
Figure 7.7 Global Growth Hormone Drugs Market Historical Revenue by Region 2016, 2027: Revenue ($m), CAGR 2016-2027 (%)
Figure 7.8 Global Growth Hormone Drugs Market by Region: AGR (%) 2012-2016
Figure 7.9 Global Growth Hormone Drugs Market by Region: Historical Market Share 2011-2016 (%)
Figure 7.10 Global Growth Hormone Drugs Market Forecast by Region: Revenue ($m), Global AGR (%), 2016-2027
Figure 7.11 Global Growth Hormone Drugs Market by Region: AGR (%) 2016-2027
Figure 7.12 Global Growth Hormone Drugs Market by Region: Market Share Forecast 2017-2027 (%)
Figure 7.13 Global Growth Hormone Drugs Market by Region: Market Share Forecast 2017 (%)
Figure 7.14 Global Growth Hormone Drugs Market by Region: Market Share Forecast 2021 (%)
Figure 7.15 Global Growth Hormone Drugs Market by Region: Market Share Forecast 2027 (%)
Figure 7.16 US Growth Hormone Drugs Market: 2016 Revenue ($m), Market Share (%)
Figure 7.17 US Growth Hormone Drugs Market Historical Sales 2011-2016: Revenue ($m), AGR (%)
Figure 7.18 US Growth Hormone Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
Figure 7.19 EU5 Growth Hormone Drugs Market 2016: Global Market Share (%)
Figure 7.20 EU5 Growth Hormone Drugs Market Countries 2016: Market Share (%)
Figure 7.21 EU5 Growth Hormone Drugs Market Historical Sales 2011-2016: Revenue ($m), AGR (%)
Figure 7.22 EU5 Growth Hormone Drugs Market Forecast Countries 2016 and 2027: Revenue ($m), CAGR 2016-2027 (%)
Figure 7.23 EU5 Growth Hormone Drugs Market by Region: Historical Market Share Forecast 2011-2016 (%)
Figure 7.24 EU5 Growth Hormone Drugs Market Forecast: Global Market Share 2027(%)
Figure 7.25 EU5 Growth Hormone Drugs Market Forecast By Country 2016-2027: Revenue ($m), AGR (%)
Figure 7.26 EU5 Growth Hormone Drugs Market By Region: Market Share Forecast 2017-2027 (%)
Figure 7.27 EU5 Growth Hormone Drugs Market Forecast by Region: Global Market Share 2027(%)
Figure 7.28 EU5 Growth Hormone Drugs Market Forecast by Region: Market Share 2017(%)
Figure 7.29 EU5 Growth Hormone Drugs Market Forecast by Region: Market Share 2027 (%)
Figure 7.30 EU5 Global Growth Hormone Drugs Market Forecast by Region: AGR 2016-2027 (%)
Figure 7.31 UK Growth Hormone Drugs Market Forecast: Revenue ($m), AGR (%),2016-2027
Figure 7.32 Spain Growth Hormone Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2027
Figure 7.33 Italy Growth Hormone Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2027
Figure 7.34 Germany Growth Hormone Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2027
Figure 7.35 France Growth Hormone Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2027
Figure 7.36 Japan Growth Hormone Drugs Market Historical Sales 2011-2016: Revenue ($m), AGR (%)
Figure 7.37 Japan Growth Hormone Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2027
Figure 8.1 Growth Hormone Drugs Clinical Trial Pipeline Segmentation by Phase, 2017
Figure 8.2 Key Late-stage Clinical Trials of VRS-317
Figure 9.1 Global Growth Hormone Drugs Market by Company: Revenue ($m)
Figure 10.1 Global Growth Hormone Drugs Market by Company: Revenue ($m)
Figure 10.2 Global Growth Hormone Drugs Market by Company 2016: Market Share (%)
Figure 10.3 Global Growth Hormone Drugs Market by Company 2011 and 2016: Revenue ($m)
Figure 10.4 Global Growth Hormone Drugs Market by Top 5 Companies 2011-2016: Revenue ($m), Global AGR (%)
Figure 10.5 Global Growth Hormone Drugs Market by Company Share 2011-2016
Figure 10.6 Global Growth Hormone Drugs Market by Company Share 2011-2016
Figure 11.1 Global Growth Hormone Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
Figure 11.2 Growth Hormone Drugs Clinical Trials Pipeline Segmentation by Phase, 2017

Companies Listed

Acsendis Pharma
Aeterna Zentaris
Alteogen
Altus Pharmaceuticals
Amgen
Biogenomics
Critical Pharmaceuticals
Eli Lilly and Co
European Medicines Agency (EMA)
Ferring Pharmaceuticals
Food and Drugs Administration (FDA)
FortuneRock
Genentech
GeneScience Pharmaceuticals
Genexine
Hanmi Pharmaceutical
Ipsen
JCR Pharmaceuticals
LG
Merck KGaA
Novartis
Novo Nordisk
Opko Health
Pfenex
Pfizer
Pharmacia and Upjohn
Roche
Roche
Sereno Laboratories
Somatropin BioPartners
Teva
Versatis
World Health Organisation (WHO)
National Institute for Health and Care Excellence (NICE)

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.

close